Fulcrum Therapeutics
About
Fulcrum Therapeutics is a Cambridge biotechnology company developing small-molecule medicines for genetically defined diseases in areas of high unmet medical need. Its approach aims to treat diseases at their root cause by modulating and balancing gene expression. The company’s discovery engine is designed to systematically identify and validate cellular drug targets that can modulate gene expression, drawing on deep study of disease biology in patient tissue samples.
The lead program, pociredir, is being investigated in clinical trials as a treatment for sickle cell disease, and the company has other programs and discovery efforts in its pipeline. Fulcrum describes its work as patient-informed discovery and patient-driven development, partnering with the patient community and letting patients’ experiences guide strategy. It shares the stories of people living with sickle cell disease who advocate for better care.
What to Know
- The company is listed with the Central Square Business Improvement District.
- Patient stories it shares come from sickle cell advocates in Boston and Baltimore.
- Fulcrum recruits for open roles and publishes its core values.
- One featured advocate uses poetry to raise awareness of sickle cell disease.
Is this your business?
Claim it to add hours, photos, a description and a spotlight story.